RxDoctor Payments Data

Brittany Peacock, DO

Family Medicine · Travelers Rest, SCNPI 1588008270

Payments from drug & device makers

$6,881in general payments, 2019–2025

Across 430 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$794
  • Lilly USA, LLC$711
  • Pfizer$410
  • Boehringer Ingelheim$367
  • Amgen$328
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,881 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$139,506
Medicare patients
270
Services billed
7,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$145,331
EliquisApixaban65$81,429
LinzessLinaclotide29$50,082
JardianceEmpagliflozin28$40,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$35,866
TrulicityDulaglutide12$29,994
Synjardy XrEmpagliflozin/Metformin Hcl22$25,526
Repatha SureclickEvolocumab27$20,572
Tresiba Flextouch U-200Insulin Degludec18$18,587
XareltoRivaroxaban14$18,067
UbrelvyUbrogepant12$17,261
MounjaroTirzepatide12$17,034
MyrbetriqMirabegron18$16,003
Breo ElliptaFluticasone/Vilanterol21$14,836
EntrestoSacubitril/Valsartan11$11,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,069$145,33194 claims
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Synjardy$367$83,78883 claims
PfizerEliquis$410$81,42965 claims
AbbVieLinzess, Ubrelvy, Synthroid$794$70,36989 claims
GSKTrelegy Ellipta, Breo Ellipta$194$50,70163 claims
Lilly USA, LLCTrulicity, Mounjaro$711$47,02924 claims
Johnson & JohnsonXarelto$13$18,06714 claims
Astellas Pharma US IncMyrbetriq$24$16,00318 claims
NovartisEntresto$310$11,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Travelers Rest

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →